| Stereochemistry | RACEMIC |
| Molecular Formula | C17H17N3O2S |
| Molecular Weight | 327.401 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(C(=O)NC1=CC2=C(C=C1)C(=O)NC=C2)C3=CSC=C3
InChI
InChIKey=VDYRZXYYQMMFJW-UHFFFAOYSA-N
InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)
| Molecular Formula | C17H17N3O2S |
| Molecular Weight | 327.401 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Verosudil (AR-12286) is a selective Rho-kinase inhibitor for the treatment of glaucoma and ocular hypertension being developed by Aerie Pharmaceuticals in the US. Verosudil was in phase II/III clinical trials for the treatment of glaucoma and in phase II clinical trials for the treatment of ocular hypertension.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
0.05%, 0.1% and 0.25% Verosudil (AR-12286) ophthalmic solutions in patients diagnosed with ocular hypertension or glaucoma. All 3 concentrations of AR-12286 produced statistically and clinically significant reductions in mean IOP that were dose dependent, with peak effects occurring 2 to 4 hours after dosing. Mean IOP at peak effect ranged from 17.6 to 18.7 mm Hg (-6.8 to -4.4 mm Hg) for the 3 concentrations. The largest IOP reductions were produced by 0.25% AR-12286 after twice daily dosing (up to -6.8 mm Hg; 28%). The 0.25% concentration dosed once-daily in the evening produced highly significant IOP reductions throughout the following day (-5.4 to -4.2 mm Hg).
Route of Administration:
Topical
